Morning stiffness and wrinkling skin are usually naturalized as obligatory aging. When you aren’t recognized by your fascia as a hunter, this atrophy accelerates. This vital connective tissue is a functional composite of collagen and hyaluronan, where collagen provides the high-tensile scaffolding and hyaluronan serves as the visco-elastic lubricant that permits low-friction sliding. Your fascia evolved to expect an ancestral supply and signal that initiate structural restoration, signals our ancestors received in massive doses but are now erased from our plates.

The Silence of the Modern Plate

Official dietary guidelines disregard hyaluronan because the molecular signal has effectively vanished from the modern plate. Neither the FDA nor the EFSA provides daily estimates, masking an institutional blind spot where modern diets provide only a residual 3 to 6 milligrams daily1.

Modern diets valorize skeletal muscle, such as skinless chicken and lean steaks. These tissues contain just 1 to 2 milligrams of hyaluronan per 100 grams; a standard steak provides a scant 5 milligrams2. Plants contain none.

The Ancestral Hyaluronan Baseline

Anthropological data from the Hadza, Ju/’hoansi, and Aché attest how whole-animal consumption maintained high hyaluronan levels3. By consuming the skin, marrow, and organs that we often throw away today, these groups made use of the richest sources of connective tissue available.

Our ancestors lived through cycles of plenty and hardship. During lean times, people on the savanna relied more on gathered plants. Still, they would have picked up some hyaluronan by getting marrow out of bones and eating small game, probably in the range of 10 to 40 milligrams. Bone broth is the last clear trace of that older pattern of eating, when connective tissues were a regular part of the diet.

A successful hunt fundamentally changed these ancestral proportions. An animal’s fascial networks, skin, and synovial fluid are saturated with hyaluronan, holding roughly 50 to 150 milligrams per 100 grams4. By utilizing the whole animal, the tribe transitioned their biological baseline into a high-saturation state, reaching a daily intake range of 150 to 350 milligrams5.

Hunter vs. Gatherer Mode

Modern diets stall the system in a permanent gatherer mode. Because the fascia no longer recognizes the hunt, it de-prioritizes structural restoration, causing the chronic stiffness we mistake for aging. Ancestrally, dietary hyaluronan operated as a metabolic governor. Consumption of a fresh kill triggered hunter mode, providing the sustained biological command and the necessary building blocks to repair the micro-architectural tears of the hunt through large-scale fascial remodeling6.

Bioavailability

A basic bioavailability problem makes the simple idea that swallowed hyaluronan travels straight to the fascia much harder to support. Its size alone prevents direct delivery to tissue. In its natural high-molecular-weight form, hyaluronan is already an enormous biopolymer, with a molecular mass that exceeds what the intestine can typically transport. It can also bind up to 1,000 times its own weight in water, which makes its effective size even larger by creating a huge hydrodynamic volume. As a result, native hyaluronan has little to no systemic bioavailability, because the intestinal epithelium acts as a size-selective barrier that keeps these large polymer chains from entering the bloodstream and reaching target tissues7.

Unlocking the Hunter Mode Supply and Signal

Your microbiome governs this transition. By enzymatically cleaving high-molecular-weight hyaluronan, specialized bacteria simulate the structural fragmentation of the hunt, releasing the specific fragments required to bypass the intestinal barrier and trigger the hunter mode signal8. This fermentation process nourishes the gut lining as a premium prebiotic thereby optimizing the Firmicutes-to-Bacteroides ratio.

Exogenous fragments alleviate the biosynthetic burden of de novo hyaluronan production, optimizing systemic metabolic efficiency9. Once absorbed, these fragments act as both the substrate supply for hyaluronan production and the biological signal for repair.

Your fascial receptors recognize the hunter through two different inputs. First, high-velocity movement initiates a signaling burst; mechanical shear tears local hyaluronan to release the precise fragment sizes that bind and trigger CD44 receptors10. Second, dietary polymers provide a sustained signal.

These large molecules act like a microbial bioreactor, fermenting slowly in the colon and supplying fascial receptors with a steady stream of fragments11. Their ongoing presence at the CD44 receptor helps maintain the hunter mode signal, which stimulates fibroblast proliferation and the production of new collagen and hyaluronan. In turn, this supports the structural remodeling needed to repair accumulated mechanical wear12.

Your CD44 receptors’ activation follows a sigmoidal curve instead of linear progression. Low background levels do nothing as the receptors require a bigger influx to cluster and trigger the repair cascade. When the receptors are saturated, adding more hyaluronan has no bigger effect. Taking ten times the clinical dose will not multiply your results ten times as the fascia is already in hunter mode13.

Measurable Outcomes for Skin and Joints

Restoring the hunter mode signal reverses structural decline. Clinical trials show that taking 120 to 240 milligrams of oral hyaluronan per day can significantly improve skin hydration and elasticity while also reducing wrinkle depth. A systematic review of seven randomized controlled trials involving 291 patients found that this daily dose led to meaningful improvements in these key measures of skin health14.

However, because these trials typically last only 8 to 12 weeks, they likely capture only the leading edge of structural repair. With the metabolic half-life of dermal collagen estimated at 15 years, these brief snapshots cannot measure the cumulative, decadal benefit of CD44-mediated collagen remodeling15. The visible restoration seen in months marks the inception of a decadal shift in the functional integrity of the internal fascia wrapping every muscle and organ.

Load-bearing joints show the most dramatic systemic repair. A systematic review covering 11 clinical trials and 597 patients found that taking 120 to 240 milligrams daily is the effective range for improving standardized osteoarthritis scores. At this dose, patients saw meaningful reductions in joint pain, stiffness, and physical dysfunction16. It also appears to restore support for synovial fluid and fascial signaling. As the extracellular matrix is rebuilt, these precursors help shift the body out of a cycle of chronic friction and back toward smoother, easier movement.

Stiff joints and sagging skin frequently reflect a system starved of hunter mode inputs, signaling a structural atrophy that we too often attribute solely to the passage of time. Restoring the supply and signal your fascia demands through bone broth (which contains other valuable substances as well) or clinical supplementation allows it to recognize the command for repair once more, ending the silence dictated by modern foodways. Restoring these ancestral proportions returns the system to hunter mode, restoring supple skin and vigorous joints.

A week ago I was skeptical about the prospect of radically reducing human sleep needs. After reading John Boyle’s Cause area: Short-sleeper genes, I decided to research the area more deeply and updated to believe that it’s more likely that we can reduce human sleep needs without significant negative side effects. It might increase risk-taking which has both positive and negative effects. The one friend I have that has short-sleeper genes is a startup founder.

Boyle suggested that one of the best actions to attempt would be using orexin or an orexin agonist as a drug, but that there’s currently a lack of funding for doing so.

Given the way the FDA and EMA work, drugs only get approved when they are able to cure illnesses, with an illness being anything that has an ICD code. According to that notion, people who suffer from having to sleep more than four hours don’t have an illness and thus drugs can’t be approved for that purpose. In practice, this results in the NIH not being interested to fund the research of Ying-Hui, about people who need a lot less sleep and are still well rested, that Boyle discussed.

DEC2-P384R and orexin biology

The DEC2 gene produces prepro-orexin, which is 131 amino acids long. People with the DEC2-P384R mutation produce more prepro-orexin and have a reduced need for sleep. From prepro-orexin our body generates orexin A, which is 33 amino acids long, and orexin B, which is 28 amino acids long. Orexin A is highly conserved and has the same molecular structure in humans, mice, rats, and cows, while human orexin B differs from rodent orexin B. While orexin B doesn’t cross the blood-brain barrier, orexin A does. I didn’t find information on whether or not prepro-orexin passes the barrier, but it likely doesn’t given its size.

According to Uniprot:

Orexin-A binds to both OX1R and OX2R with a high affinity, whereas orexin-B binds only to OX2R with a similar high affinity.

The literature is sometimes unclear when they use the term orexin about whether the author means prepro-orexin, orexin A, and orexin B or a mix of them. Hypocretin is an alternative name in the literature for orexin, hypocretin-1 for orexin A, and hypocretin-1 for orexin B.

Do we get a free lunch?

From an evolutionary perspective, it seems beneficial to have a lower sleep requirement, so we have to ask ourselves why DEC2-P384R didn’t provide a significant enough advantage to spread the mutation to the whole human population.

Energy expenditure hypothesis

In the search for evolutionary disadvantages, I found an article by Dyan Sellayah et al where they say:

Here, we review a fat-burning mechanism that is turned on by the brain hormone orexin during high-caloric food consumption. Remarkably, the same hormone also induces feeding, and its levels correlate with lean body mass in both rodents and humans. Intriguingly, loss of orexin prevents thermogenic energy expenditure while inducing obesity in the face of hypophagia. Thus, orexin is a unique neuropeptide that promotes both feeding and energy expenditure, conferring resistance to weight gain.

Evolutionarily, for most of human history, a mutation that caused someone to eat more while burning their fat reserves for thermogenic energy, instead of using the energy for necessary metabolic processes, was a clear disadvantage.

This makes me hopeful that in our current world, where we have access to as much food as we want, DEC2-P384R comes without clear negative side effects.

Stress hypothesis

The cavefish Astyanax mexicanus has evolved to need 80% less sleep compared to related surface fish, while having a similar lifespan. Astyanax mexicanus have OX2R receptors that are more sensitive, and have an increased blood level of orexin.

A key environmental difference for Astyanax mexicanus is that they live in an environment without predators. This makes them less anxious, and it’s plausible that increasing orexin will make people less anxious and more willing to take risks.

If that’s what comes with reducing human sleep needs, we might be okay with it. Sleeping less, having a stronger drive for action, and willingness to take more risks sounds like a good package in today’s environment for most people. It might be negative for individuals with high aggression or low IQ who are more likely to commit crimes if they feel less inhibition.

If we need sleep to deal with the effects of stress, it makes sense for genes that reduce stress to lead to less sleep. This hypothesis would also be supported by some people who need less sleep after meditating a lot, given that meditation is another way to reduce stress.

Orexin and narcolepsy

Lucie Barateau et al write in Treatment Options for Narcolepsy:

Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy absent.

Given that orexin A (hypocretin-1) passes the blood-brain barrier while orexin B doesn’t, it’s possible to measure orexin A deficiency in the blood but not measure whether or not someone is orexin B deficient. Narcolepsy type 1 patients are likely both orexin A and orexin B deficient. Narcolepsy type 1 is estimated to have a prevalence of 25 to 50 per 100,000 people according to UpToDate. In a double-blind experiment intranasal orexin A supplementation of patients with Narcolepsy type 1 helped them with having faster reaction times and making fewer errors.

If you are a naive reader, you might expect that we give people with narcolepsy type 1 orexin-A as a supplement because that would be obvious. We don’t. You might expect that someone tried to bring it to market as a drug and ran a clinical trial. They didn’t.

The problem seems to be that the solution is too obvious. The patent office likely decided that the solution would be too obvious to give out a patent for it, and thus the narcoleptic patients are without orexin-A supplementation unless they go through efforts to procure it themselves.

Clinical trials

Instead of giving patients orexin-A, multiple companies recently invested in clinical trials for orexin agonists. An orexin agonist is a substance that binds to the orexin receptors just like orexin does. Unfortunately, when you select a molecule for binding to a certain receptor you are generally choosing molecules that easily bind in general, which often leads to off-target effects where other receptors are also affected.
Scott Alexander’s post on how his hospital pharmacy didn’t have any melatonin but only what’s effectively an expensive melatonin agonist is worth reading to understand the problem of how hard it is for unpatented natural substances to exist in our medical system.

Researchers at Takeda got breakthrough therapy status for their oral orexin agonist to treat narcolepsy type 1, but their trial ended prematurely because a safety signal emerged in the trial. The likely hypothesis for the safety signal is that their drug not only binds to the orexin receptors but also has other interactions, which is a common problem when developing artificial agonists instead of the natural substance to which the body is already adapted.

Fortunately, there are more clinical trials underway for orexin agonists for narcolepsy type 1.

Possible actions

We can hope that the clinical trials for orexin agonists find a drug that gets approved for Narcolepsy type 1 patients, and then non-narcoleptics can use that drug off-label.

We could fund studies for orexin-A supplementation with philanthropic money with the hope of both helping Narcolepsy type 1 patients, and using the drug after it got FDA approval off-label to reduce sleep needs in the general population. Given that there’s a market failure because of the inability to patent orexin-A as a treatment, using philanthropic money has justification. This approach has the benefit that orexin-A would be available without patent protection, and thus a lot cheaper to procure.

Daring individuals might buy orexin-A from a nootropics store and experiment themselves. It helped rhesus monkeys to deal better with sleeping less than their normal amount of hours. If you think about it, then I would recommend that you do additional research in addition to what you read from me. This post is very much not medical advice.

The cavefish seem to eat more in an environment with plenty of food than the surface fish and have less stress. We want our farm animals to eat a lot and have less stress. From an animal welfare standpoint, replacing the orexin system of chicken, pigs, or cows with the orexin system of cavefish might help them be happier and be economically beneficial. This might make sense as an EA startup. You get more happy animals and potentially show that reducing sleep needs in a nonhuman species works well enough to motivate us to invest research dollars into reducing human sleep needs.

Invest more into researching the other short sleeper genes that interact with different systems than the orexin system.

Trying to figure out what’s what in the world of wellness and performance boosters can feel like walking through a minefield, especially when something like BPC-157 kicks up so much dust. Within certain circles, it gets talked about a lot: a powerful healing peptide, a game-changer for recovery. It’s all over online forums, biohackers swear by it, and some clinics even offer it. But here’s the catch that makes it tough to know what to believe: for all this buzz, BPC-157 hasn't gotten the nod from the FDA, nor is it widely accepted by mainstream medicine.

This isn't just an academic puzzle; it's personal. When we're injured or in pain, we're all looking for something that helps. When our health is in jeopardy, treatments that heal are invaluable. At the same time, treatments that do nothing or even worse have bad side effects can cost us dearly in time and money. So, how do we weigh the exciting claims about BPC-157 when solid proof is hard to find, its backstory is a bit hazy, and the personal stories sound so compelling? More to the point, what does the actual evidence say about whether BPC-157 works? This is bigger than just one compound. It’s about how we make choices about our health when we’re faced with uncertainty. Whether it's a supplement, a new therapy, or a tip from a friend, our best guide is our clear thinking. That’s why I put this piece together: to explore what it looks like to carefully and rationally examine health claims, especially when the promises seem to outrun the proof, and how this kind of thinking can help us make smarter choices for our well-being.

What Makes BPC-157 Seem Like a Promising Healing Peptide

BPC-157 has certainly built up a reputation as a kind of underground miracle. People talk it up for its supposed ability to speed up healing, calm inflammation, and help the body recover in all sorts of ways, from joints and gut health to the nervous system. Its origin story, with its roots in less-than-mainstream science and early lab claims, only adds to its mystique. It’s part of a growing list of "healing peptides" that promise results beyond what standard medicine typically offers. Online, you’ll find plenty of stories about amazing recoveries, quick healing after surgery, and relief from injuries that just wouldn’t quit.

Blogger Troof, for instance, did a big survey on nootropics where thousands of people shared their experiences with various substances, including BPC-157. His findings put BPC-157 in an interesting spot: "uncommon-but-great." This meant not a ton of people had tried it, but those who did often said it had strong effects. Based on his number-crunching, Troof suggested BPC-157 was "likely one of the most beneficial compounds in the dataset," with somewhere between 2% and 13% of users calling their experience with it "life-changing."

If it works, a peptide like BPC-157 could be a game-changer for recovering from injuries and dealing with chronic pain, areas where today’s medicine often doesn’t have all the answers. But big claims need a hard look, and that’s where I started digging. This wasn't just a random project for me. I carry the daily reality of significant surgical scars; these aren't just surface marks, they create deep fascial tensions that pull on my inner organs. BPC-157 healing them or reducing their impact, that would be wonderful.

In 2022, the World Anti-Doping Agency (WADA) banned BPC-157, saying there wasn’t enough proof it was safe or effective for humans. Ironically, for many in the biohacking and sports worlds, this ban just seemed to confirm that BPC-157 must be pretty powerful stuff.

What I Found When I Looked Closer

If BPC-157 genuinely helps the body heal, there ought to be a clear biological reason for how it does it. We usually know how drugs do their job: they could bind to cell receptors, change how enzymes work, or affect our genes. Knowing this helps all of us get a handle on what a drug might do for us and what the risks could be. Healing means tissue growth, and not all growth is good news. A substance that speeds up repair could, in theory, also encourage harmful cells to grow, including cancerous ones. That’s a gamble I’m not willing to take without more information.

So, I started by trying to find the protein that BPC-157 supposedly comes from. I figured that would shed some light on how it works. But when I searched NCBI’s protein database, I came up empty. There was no known natural protein with the BPC-157 sequence. I even posted on Biology Stack Exchange, and despite several people trying to help, nobody could find a match in Uniprot either.

Bryan Krause, a biostatistician and neuroscientist who replied, pointed out serious red flags in BPC-157's origin story. He wondered how scientists back in the 1980s could have isolated a peptide and claimed it had such wide-ranging healing powers in such a short timeframe, especially with a name like 'Body Protection Compound'. Early reports say the peptide was taken from human gastric juice and named "Body Protection Compound," a name that suggests it’s a cure-all before any solid testing was done. In science, you usually get the results first, then pick a name, not the other way around. Krause also stressed that almost all the early research came from one lab in Zagreb, which had close ties to the company holding the patent in Croatia. This kind of situation makes independent checking important, but that’s largely missing here. Put together, these points make you seriously question the story of how BPC-157 was developed, and that casts a shadow over the science said to support it.

Now, there are a couple of studies on BPC-157 that weren't from that Zagreb lab: one from Taiwan looking at blood vessel effects, and another from China on how the body processes it. These might look like independent proof, but we should be careful not to read too much into them. Both papers take the peptide's legitimacy for granted, without digging into the serious questions about where it came from or if it even makes sense biologically. Their findings build on the Zagreb lab's work without really challenging or trying to replicate it. So, these studies add to the story, but they don't confirm it.

Think about it: if BPC-157 worked through some new, amazing healing pathway, wouldn't pharmaceutical companies be all over it? They could develop drugs to target that pathway, even if they didn't use BPC-157 itself. In this scenario, the drive for profit in Big Pharma would line up with the scientific goal of finding real, usable healing mechanisms. The fact that this kind of intense research interest hasn't materialized is pretty telling.

The Three Major Failings of BPC-157

To get why the BPC-157 story doesn't hold up, we need to look at three big, interconnected problems. Spotting these kinds of issues can help us all make clearer judgments about health claims, instead of just taking them at face value:

The whole situation starts to feel a bit like homeopathy. Just like BPC-157, homeopathy has some low-quality studies and lots of personal stories supporting it, but it’s missing strong, independently repeated evidence and a believable biological explanation. This isn't just a casual jab. In both cases, public excitement has run way ahead of scientific proof. Without solid data or a plausible way it could work, belief ends up being more about the story than the substance.

1. No Biological Mechanism: If BPC-157 truly helps healing, it should work through known biological channels, like interacting with cell receptors, enzymes, or genes. But no one has shown this, and the protein it supposedly comes from is nowhere to be found in any biological database. This is strange. Thousands of scientists are actively studying peptides and proteins involved in tissue repair. If a compound really had powerful effects here, you’d expect a flurry of research, investigation, and debate about how it works. The silence from the broader scientific community suggests there’s no convincing biological reason for BPC-157’s claims. And if we don’t know how it works, we can’t really know its benefits or its dangers.

2. Weak Independent Evidence: While those couple of studies from labs in Taiwan and China might seem like a good sign, they lean heavily on the unverified claims from the Zagreb lab. They don't tackle the missing biological mechanism, the questionable origin story, or the lack of repeated findings by others. The fact that these are the only known labs outside Croatia to publish on BPC-157 just shows how little real scientific interest the peptide has drawn. In the world of academic research, where there's pressure to publish and follow trends, studies like these can sometimes just keep a story going rather than truly testing it.

3. A Suspicious Origin Story: The story of BPC-157’s discovery is full of warning signs. It was dubbed "Body Protection Compound" before there was any solid proof it did anything, basically, assuming it worked instead of proving it. Most of the early research came from that single lab in Zagreb connected to the patent holder, and there has been very little, if any, independent work to back it up since.

What To Do With All This Uncertainty

When you're looking at a claim like the ones for BPC-157, there are usually three possibilities: (1) the evidence backs it up, (2) there’s not enough evidence to say one way or the other, or (3) the evidence suggests it doesn’t actually work. New treatments often start in that second category. But BPC-157 isn't new; it's been around for decades. If it really offered major health benefits, you’d expect to see much stronger positive signals by now. That lack of strong evidence pushes it firmly into the third category, where the signs point to it not working. At this stage, we're not just looking at an exciting origin story anymore; we're facing the likelihood that there was never a solid foundation to begin with.

You don’t have to just give up because there are no human trials. BPC-157 isn't some brand-new, obscure compound. It’s had plenty of time to be properly tested. That long history gives us more than enough information to think rationally about it and see where the gaps are.

But this isn't just about BPC-157. It’s about how we react when a health claim sounds promising, but the evidence just isn’t there. Real critical thinking isn’t about shrugging and saying, "Who knows?" It’s about asking the right questions, figuring out what would count as actual proof, and noticing when that proof is missing. Thinking carefully about how things might work and whether the source is credible isn't just an extra step; it’s what protects us from being swayed by convincing but ultimately empty claims.

So, the next time you hear about a compound that’s supposed to be "game-changing" or "miraculous", ask if it behaves like something real. Ask what kind of biological process could explain it. Ask if the evidence truly supports that explanation. I went into this whole BPC-157 investigation with hope, hope that maybe, just maybe, there was something out there that could help me heal better from the long-term effects of surgery. What I found instead was a crucial reminder: when our health is on the line, as it is for so many of us, thinking carefully is one of the most honest and important ways we can take care of ourselves. It’s the kind of thinking that empowers us to take charge of our health decisions, especially when the path isn't clear.

📌 Bottom Line: BPC-157 in 3 Sentences

• Despite a lot of enthusiastic personal stories and survey results, BPC-157 doesn't have a known biological mechanism of action, and the protein it supposedly comes from can't be found in modern databases.

• Most of the published research comes from a single lab in Zagreb, Croatia. The few studies from other countries (two labs in Taiwan and China) seem to accept the original claims without much critical checking.

• When you look at it rationally, there’s no strong reason to believe BPC-157 actually works. Its popularity seems to be built on anecdotes rather than solid evidence, much like what you see with homeopathy, where compelling stories often overshadow a lack of credible proof.

Feel free to share this summary if you're in a BPC-157 debate; it’s a shortcut through the fog.